Multicenter, USA - 04 Apr `17Incyte: A Study of Ruxolitinib 1,5% cream

Official Title: A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

In Brief: The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.

Description: Ruxolitinib cream 1.5% twice-daily for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension

Details: Check Incyte announcement or download pdf with a scientific presentation from UMass.

Ages Eligible: 18 Years to 75 Years

Start Date: April 19, 2017

Completion Date (estimated): September 2021

Status: Active, not recruiting

Study ID from ClinicalTrials.gov: NCT03099304
Other Study ID Numbers: INCB 18424-211 

Location: 26 locations across the United States

Contact: To learn more about this study, you or your doctor may contact Incyte Corporation Call Center by phone +800 00027423 or email globalmedinfo@incyte.com. Please refer to this study by its NCT number.

FAQOther Questions

  • Is vitiligo contagious?

    Vitiligo is NOT contagious. It cannot be passed on or caught from touching someone with vitiligo, shaking hands, swimming in the same pool, sharing towels, sitting next to someo...

  • Can chemicals cause vitiligo?

    It’s important to remember there are multiple factors involved in vitiligo onset, including genetic predisposition, living and working environments, and exposure to certain chem...

  • How can I explain vitiligo to my children?

    Vitiligo can be puzzling for a child because a person who has it isn't "ill" in a common sense.  To choose the right words to explain vitiligo diagnosis to a child, first consi...